Abbott Laboratories (ABT) Financial News - Abbott’s Freyman Says Humira Gained Market Share in Crohn’s, Psoriasis

Abbott Laboratories (ABT)

Abbott’s Freyman Says Humira Gained Market Share in Crohn’s, Psoriasis

Quote: Abbott Laboratories (ABT)’ top-selling drug, Humira, surged 25 percent after wresting sales from rival treatments for psoriasis and Crohn’s disease, Chief Financial Officer Thomas Freyman said. “We’re seeing an acceleration of market growth for that product and improved market share, particularly in the Crohn’s disease and psoriasis areas,” Freyman said in a telephone interview. “We’ve also made some progress in rheumatoid arthritis.” Humira, a treatment for autoimmune disorders that accounts for about one-fifth of Abbott’s revenue, brought in $2 billion in the second quarter. That contributed to a 9 percent gain in the company’s sales from a year earlier. Earnings jumped 50 percent to $1.94 billion, helped by a one-time tax benefit of $594 million, the Abbott Park, Illinois-based company said today in a statement. Pennsylvania, which holds 1.2 million of the company’s shares. “The uptake of this drug continues well beyond most analysts’ expectations.” Abbott slipped 49 cents to $52.40 at 4:02 p.m. in New York Stock Exchange composite trading. The shares have gained 9.4 percent this year. Stent Sales Chicago, in a telephone interview. Sales of artery-opening heart stents and diabetes supplies also declined, after taking out gains for currency-exchange rates, he said. “Expectations may have been even higher than what they delivered,” he said in a telephone interview. “In our view, it was a very solid quarter.” Abbott raised its forecast for full-year profit to $4.58 a share to $4.68 a share, from as much as $4.64 a share. Japan, said Larry Peepo, Abbott’s investor-relations director, on a conference call with analysts. New indications may add $1 billion to the treatment’s peak sales, he said. “Globally, we’re just seeing good market growth, good share performance and very good execution,” Freyman, the CFO, said on the call. $6.5...
Open whole article (external link)

Other Financial and Stock Market News concerning Abbott Laboratories

Abbott Laboratories Stock Summary

Abbott Laboratories manufactures and sells health care products worldwide. The company?s Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. The company?s Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors. The company was founded in 1888 and is based in Abbott Park, Illinois.